The VISKA Approach
At VISKA.BIO, we propose a unique way to target cancer through the body's innate immune system. Our innovative fusion protein will act to kill circulating cancer cells and prevent recurrence of cancer.
We have accomplished construction of a fusion protein which binds tightly to target EGFR and has substantial xanthine oxidase (XO) activity.
The fusion protein kills tumor cells expressing EGFR and elicits immunogenic cell death markers from dying cells, including surface calreticulin, HMGB1, and extracellular ATP.